Two-stage design for phase I--II cancer clinical trials using continuous dose combinations of cytotoxic agents (Q6642051)
From MaRDI portal
 | This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use this page instead for the normal view: Two-stage design for phase I--II cancer clinical trials using continuous dose combinations of cytotoxic agents |
scientific article; zbMATH DE number 7947976
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Two-stage design for phase I--II cancer clinical trials using continuous dose combinations of cytotoxic agents |
scientific article; zbMATH DE number 7947976 |
Statements
Two-stage design for phase I--II cancer clinical trials using continuous dose combinations of cytotoxic agents (English)
0 references
21 November 2024
0 references
Bayesian adaptive design
0 references
cancer phase I--II trials
0 references
cubic splines
0 references
drug combination
0 references
escalation with overdose control
0 references
maximum tolerated dose
0 references
